Wound Healing News and Research

RSS

Changes in normal glycan behavior lead to fatal lysosomal disease, say researchers

From the neurons that enable thought to the keratinocytes that make toenails grow-a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body.

6 Jun 2013

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.

6 Jun 2013

Growth factor helps hair follicles regenerate during wound healing process, say researchers

Researchers in the Perelman School of Medicine at the University of Pennsylvania have determined the role of a key growth factor, found in skin cells of limited quantities in humans, which helps hair follicles form and regenerate during the wound healing process.

3 Jun 2013

Scientists report that human scabs have become model for advanced wound dressing material

Human scabs have become the model for development of an advanced wound dressing material that shows promise for speeding the healing process, scientists are reporting. Their study appears in the journal ACS Applied Materials & Interfaces.

30 May 2013

Study suggests possible way to halt cancer development in premalignant cells

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

24 May 2013

TSRI scientists devise new technique to find therapeutic antibodies

Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents.

24 May 2013

New data highlights urgent crisis posed on US healthcare system by DFUs and VLUs

Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy) demonstrating the significant healthcare resource and economic burden that diabetic foot ulcers and venous leg ulcers place upon the US healthcare system.

23 May 2013

Novel medicine for chronic wound treatment

Every 20 seconds, a limb is lost as a consequence of diabetic foot ulcer that does not heal. To date, medical solutions that can change this situation are very limited.

20 May 2013

Certain varieties of clay have ability to kill MRSA, says ASU researcher

In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.

20 May 2013

Study: VEGF inhibitor appears to improve glaucoma surgical outcomes

The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.

18 May 2013

New research reveals how endothelium maintains highly efficient barrier function

The endothelium, the cellular layer lining the body's blood vessels, is extremely resilient. Measuring just a few hundred nanometers in thickness, this super-tenuous structure routinely withstands blood flow, hydrostatic pressure, stretch and tissue compression to create a unique and highly dynamic barrier that maintains the organization necessary to partition tissues from the body's circulatory system.

17 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

UCSF study focuses on vexing problems of handling skin cancers among elderly patients

Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.

30 Apr 2013

Genes play role in wound healing, regulate biological processes in human skin

Biologists at UC San Diego have identified eight genes never before suspected to play a role in wound healing that are called into action near the areas where wounds occur.

26 Apr 2013

Experts and patients share tips on preventing skin cancer

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers.

26 Apr 2013

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.

19 Apr 2013

St. Mary Medical Center completes expansion of Emergency Department and Trauma Center

St. Mary Medical Center has completed Phase 2 of its Emergency Department and Trauma Center expansion. To celebrate this event, a ribbon-cutting ceremony was held Tuesday, April 9, at 9 a.m., in the newly renovated Emergency Department.

10 Apr 2013

Transient electronics relieve pain, fight infection and dissolve harmlessly

Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.

9 Apr 2013

Fruit fly study offers clues to wound healing

A person's skin and a fruit fly's exoskeleton, called a "cuticle" may not look alike, but both coverings protect against injury, infection, and dehydration.

6 Apr 2013